ESTRO 2024 - Abstract Book

S2408

Clinical - Urology

ESTRO 2024

In contrast to the control group, the high-dose group had a higher percentage of patients (75%) in the high or very high-risk categories, with 33% of patients concurrently undergoing combined hormonal therapy. The median follow up period extended to 74.0 months (range: 5.3-117.0 months). For the 60 patients enrolled, the 5-year OS rate was 91.7%, and the 7-year OS rate was 81%, with a median OS of 104.09 months (range: 96.46-111.71 months ). In the high-dose group, the 5-year survival rate was 88.9%, and the 7 year survival rate was 66.7%, while the control group exhibited a 5-year survival rate of 92.5% and a 7-year survival rate of 83.4% (p=0.402). The tumor-specific OS rates at 5 years and 7 years were 95.9% and 89.9%, with a median tumor-specific OS of 111.17 months (range: 105.63-116.70 months ). In terms of prostate-specific survival, the high dose group exhibited a 5-year OS rate of 88.9% and a 7-year OS rate of 88.9%, while the control group achieved a 5 year OS rate of 97.4% and a 7-year OS rate of 90.5% (p=0.480). In the entire cohort of 60 patients, the 5- and 7-year bPFS rates were 83.2% and 70.2%, with a median bPFS of 94.13 months (range: 86.1-102.2 months). Regarding biochemical control, the high-dose group demonstrated a 5-year survival rate of 91.7% and 7-year survival rate of 91.7%, whereas the control group displayed a 5-year survival rate of 82.1% and a 7-year survival rate of 67.4% (p=0.497). In univariate analysis, a notable finding indicated that an elevated Gleason score was linked to impaired biochemical control (p=0.028). Additionally, in alignment with prognostic stratification, patients with more adverse classifications, showed suboptimal biochemical control (p=0.028). Over 5- and 7-year, the cohort consistently showed LC rates of 95.7% and 95.7% respectively, with an average of 113.9 months (range: 109.6-118.1 months). In the context of local control, the high-dose group achieved 7-year survival rates of 100%, while the control group had 7-year survival rates of 95.1%( p=0.569). Similarly, DMFS rates at 5-, and 7-year were 96.2%, and 82.3% respectively, averaging 99.8 months(range: 93.10-106.6 months). The high-dose group had a 5-year and 7-year DPFS rate of 91.7% and 91.7%, while the control group had rates of 97.6% and 81.6% respectively (p=0.918). Univariate analysis revealed that patients with underlying health conditions were less prone to distant metastasis than those without such conditions (p=0.047). The majority of patients exhibited good tolerability to SBRT, with no Grade 3 or higher adverse reactions observed in any of the patients.